PROTIA certified as an ‘innovative medical device company’ by the Ministry of Health and Welfare.

Each product is manufactured using patented technology with unique advantages that reflect customer needs. ================================================================================= ========

<2023-12-22>

Protia (303360, formerly Proteometech), a company specializing in in vitro diagnostic medical devices, announced that it has been certified as a medical device 'innovative leap forward company' in accordance with the Innovative Medical Device Company Certification Status Notice revised and issued by the Ministry of Health and Welfare.

The certification period is a total of 3 years from January 1, 2024 to December 31, 2026. The Ministry of Health and Welfare certifies medical device companies with excellent research and development investments as innovative medical device companies in accordance with the Medical Device Industry Act. According to the certification status, a total of 46 companies have been certified as innovative medical device companies, including 10 new companies on the 2024 innovative medical device company certification list. If you obtain certification as an innovative medical device company, you will be given additional points when applying for government-led research and development projects and market entry support projects. Additionally, when expanding overseas, you will receive support for joint research and clinical trials with overseas medical institutions and companies.

Protia's products are manufactured based on the company's patented technology with unique advantages. In particular, the company has established itself as a global leader in multiple allergy diagnosis with its highly integrated diagnostic products that can test allergens through blood. It provided customers with a variety of information about allergy-causing substances, and also increased the hospital's testing efficiency through accurate diagnosis, on the basis of parellel line array technology with 50, 64, 96 and 128 lines. The next-generation product, scheduled to be released next year, plans to expand sales by increasing the number of allergies that can be diagnosed to 192 and providing information on which foods patients should avoid and how to improve the environment. In addition, the company has the technology to produce, and purify over 320 types of allergen substances, enabling a flexible response to market demands. Accordingly, allergy diagnosis products can be developed customized for each country and continent, making customized sales possible.

Protia's CEO, Dr. Lim said, “We are very honored to be selected as an innovative medical device company along with leading medical device companies in Korea.” He added, “We will continue to pursue innovation-leading medical devices through continuous research and development.” he said.

​